Ubs Asset Management Americas Inc Stoke Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 107,240 shares of STOK stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,240
Previous 82,802
29.51%
Holding current value
$2.88 Million
Previous $550,000
121.27%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding STOK
# of Institutions
139Shares Held
57.6MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$145 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$145 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$137 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$124 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$117 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.06B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...